Biological Psychiatry Global Open Science
June 4, 2026
Petr Adámek, Veronika Rudolfová, Kristýna Malenínská et al.
Schizophrenia research has traditionally viewed visual processing abnormalities as downstream consequences of cortical dysfunction. However, the epidemiological observation that congenital cortical blindness appears to confer protection against schizophrenia, while peripheral blindness, regardless of its developmental timing, does not, indicates that visual input itself may play a more...
Therapeutic Advances in Psychopharmacology
2026
Veronika Andrashko, Tomáš Novák, Miloslav Kopecek et al.
Ketamine is a rapid-acting antidepressant with robust evidence, but unclear predictors of therapeutic response. Based on previous knowledge, hemodynamic parameters and acute altered state of consciousness have been hypothesized as potential correlates of subsequent antidepressant outcome. A post hoc analysis was performed using the data from an open-label study, in which 39 patients with...
Biological Psychiatry Global Open Science
September 1, 2025
Čestmír Vejmola, Klára Šíchová, Kateřina Syrová et al.
4 citations
Psychedelics, particularly psilocin, are increasingly being studied for their mind-altering effects and potential therapeutic applications in psychiatry. Visual hallucinations, especially the illusion of motion in static images, are a hallmark of their action. Despite growing interest, the underlying mechanisms remain poorly understood, as their systematic evaluation in both humans and animals...
Pharmacological reports : PR
June 16, 2025
Tereza Klučková, Marek Nikolič, Filip Tylš et al.
4 citations
Recent studies intensively explore psilocybin's antidepressant potential, but variables like previous experience, repeated use, setting, and sex remain underexplored. This study examines acute and long-term effects of psilocybin in healthy individuals. A double-blind, placebo-controlled, cross-over study included 40 healthy participants (20 females, mean age 38). Each received two doses of...
Pharmacology, biochemistry, and behavior
December 1, 2024
Lucie Olejníková-Ladislavová, Michaela Fujáková-Lipski, Klára Šíchová et al.
5 citations
Mescaline is a classical psychedelic compound with a phenylethylamine structure that primarily acts on serotonin 5-HT2A/C receptors, but also binds to 5-HT1A and 5-HT2B receptors. Despite being the first psychedelic ever isolated and synthesized, the precise role of different serotonin receptor subtypes in its behavioral pharmacology is not fully understood. In this study, we aimed to...
bioRxiv Preprint Server
August 28, 2024
Lucie Olejníková-Ladislavová, Michaela Fujáková-Lipski, Klára Šíchová et al.
preprint
Rationale Mescaline is a classical psychedelic compound with a phenylethylamine structure that primarily acts on serotonin 5-HT2A/C receptors, but also binds to 5-HT1A and 5-HT2B receptors. Despite being the first psychedelic ever isolated and synthesized, the precise role of different serotonin receptor subtypes in its behavioral pharmacology is not fully understood.
IBRO Neuroscience Reports
November 6, 2023
Tomáš Páleníček, Tereza Klučková, Marek Nikolič et al.
INTRODUCTION: The mechanisms by which the psychedelic drug psilocybin, a novel rapid-acting antidepressant, improves depressive symptoms are still unclear. One candidate mechanism is the impact of the phenomenology of the psychedelic experience, with positive phenomenology hypothesised to be associated with positive long-term outcomes and fearful phenomenology hypothesised to be associated with...
Frontiers in Pharmacology
2023
Kateřina Syrová, Klára Šíchová, Hynek Danda et al.
4 citations
Introduction: N-2-methoxy-benzylated ("NBOMe") analogues of phenethylamine are a group of new psychoactive substances (NPS) with reported strong psychedelic effects in sub-milligram doses linked to a number of severe intoxications, including fatal ones. In our present work, we provide a detailed investigation of pharmacokinetics and acute behavioural effects of 2C-B-Fly-NBOMe...
Frontiers in Psychology
2017
Marek Havlík, Eva Kozáková, Jiří Horáček
In this review, we deal with two central questions of consciousness how and why, and we outline their possible future development. The question how refers to the empirical endeavor to reveal the neural correlates and mechanisms that form consciousness. On the other hand, the question why generally refers to the "hard problem" of consciousness, which claims that empirical science will always...
Psychopharmacology
2013
Tomáš Páleníček, Michaela Fujáková, Martin Brunovský et al.
51 citations
Behavioral, neurochemical and pharmaco-EEG profiles of a new synthetic drug 4-bromo-2,5-dimethoxyphenethylamine (2C-B) in rats were examined. Locomotor effects, prepulse inhibition (PPI) of acoustic startle reaction (ASR), dopamine and its metabolite levels in nucleus accumbens (NAc), EEG power spectra and coherence in freely moving rats were analysed. Amphetamine was used as a reference...
Pharmacology, biochemistry, and behavior
March 2011
Tomáš Páleníček, Marie Balíková, Miroslava Rohanová et al.
Despite poisoning with the ecstasy substitute para-methoxymethamphetamine (PMMA) being typically associated with severe hyperthermia and death, behavioral and toxicological data on this drug are missing. Herein we present the behavioral profile of PMMA, its hyperthermic potency and pharmacokinetic profile in rats. The effects of PMMA 5 and 20 mg/kg on locomotion, on prepulse inhibition (PPI) of...
Progress in neuro-psychopharmacology & biological psychiatry
May 30, 2010
Tomáš Páleníček, Zdenek Hlinák, Vĕra Bubeníková‐valešová et al.
The aim of this study was to describe sex differences in the behavioural effects of N,N-diethyllysergamide (LSD) (locomotor activity and other behavioural repertoire in the open field) and its effects on sensorimotor gating in rats (prepulse inhibition (PPI) of the acoustic startle reaction). Three groups of animals were analysed: males, oestral and pro-oestral phase females (EP females), and...
Neuroscience and Biobehavioral Reviews
July 1, 2008
Vĕra Bubeníková‐valešová, Jiří Horáček, Monika Vrajová et al.
The research of the glutamatergic system in schizophrenia has advanced with the use of non-competitive antagonists of glutamate NMDA receptors (phencyclidine, ketamine, and dizocilpine), which change both human and animal behaviour and induce schizophrenia-like manifestations. Models based on both acute and chronic administration of these substances in humans and rats show phenomenological...